Cargando…

Quality of Health Economic Studies (QHES) - Tool or Mask?

Detalles Bibliográficos
Autor principal:	Curtiss, Frederic R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2003
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437194/ https://www.ncbi.nlm.nih.gov/pubmed/14613374 http://dx.doi.org/10.18553/jmcp.2003.9.1.93a

Ejemplares similares

Assessing the Value of the Quality of Health Economic Studies (QHES)
por: Motheral, Brenda R.
Publicado: (2003)

Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES
por: Ofman, Joshua J., et al.
Publicado: (2003)

Quality Improvement Opportunities in Prescriber Alert Programs
por: Curtiss, Frederic R.
Publicado: (2010)

What Do We Really Know About VBID? Quality of the Evidence and Ethical Considerations for Health Plan Sponsors
por: Fairman, Kathleen A., et al.
Publicado: (2011)

Rethinking the Whodunnit Approach to Assessing the Quality of Health Care Research -- A Call to Focus on the Evidence in Evidence-Based Practice
por: Fairman, Kathleen A., et al.
Publicado: (2008)

Chasing Quality - Clinical Practice Guidelines and HEDIS Measures of Asthma and Depression Therapy Management
por: Curtiss, Frederic R.
Publicado: (2006)

HIPAA Effects on Health Research and PBM Functions in Drug Utilization Review
por: Curtiss, Frederic R.
Publicado: (2003)

Clinical Quality Indicators and Provider Financial Incentives: Does Money Matter?
por: Fairman, Kathleen A., et al.
Publicado: (2010)

Clinical Pharmacist Interventions to Bridge the Quality Chasm and Methods Necessary to Hold Quality Improvement Gains
por: Curtiss, Frederic R.
Publicado: (2004)

How Do Seniors Respond to 100% Cost-Sharing for Prescription Drugs? Quality of the Evidence Underlying Opinions About the Medicare Part D Coverage Gap
por: Fairman, Kathleen A., et al.
Publicado: (2011)

Antihypertensive Drug Effects on Renal Function and Myocardial Infarction and Implications of the ALLHAT Study Results
por: Curtiss, Frederic R.
Publicado: (2003)

Managed Care and Health Care Reform: Everything Old Is New Again
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Does Medicalization of Life Imperil Health? Expanding Indications for Diagnosis and Treatment of Chronic “Disease”
por: Fairman, Kathleen A., et al.
Publicado: (2011)

Selling Real-World Health Care Research to Reluctant Buyers-Evidence-Based Education or Marketing a Defective Product?
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Still Looking for Health Outcomes in All the Wrong Places? Misinterpreted Observational Evidence, Medication Adherence Promotion, and Value-Based Insurance Design
por: Fairman, Kathleen A., et al.
Publicado: (2009)

Lessons Learned from Randomized Trials and Recent Experience with Health Information Technology: Promising Interventions Meet Real-World Patient Care
por: Fairman, Kathleen A., et al.
Publicado: (2010)

David and Goliath - Employer Takes on Health Care Cost Management
por: Curtiss, Frederic R.
Publicado: (2004)

Preventing Medication Errors and Adverse Drug Events
por: Curtiss, Frederic R.
Publicado: (2003)

Prior Authorization to Manage Drug Utilization and Costs
por: Curtiss, Frederic R.
Publicado: (2003)

Burden of Prescription Drug Costs in the United States
por: Curtiss, Frederic R.
Publicado: (2003)

Medicare PPOs and Managed Care
por: Curtiss, Frederic R.
Publicado: (2003)

Who Needs XR, LA, SR, XL, ER, or CR?
por: Curtiss, Frederic R.
Publicado: (2005)

What Is the Future of Thiazolidinediones (TZDs) After Market Introduction of Inhaled Insulin?
por: Curtiss, Frederic R.
Publicado: (2006)

COX-2 Inhibitors: Little or No GI Protection, Increased Risk of Cardiovascular Events, High Cost, and Other Class-less Effects
por: Curtiss, Frederic R.
Publicado: (2005)

Measuring Value in the Treatment of Symptoms of Allergic Rhinitis With Nasal Steroids
por: Curtiss, Frederic R.
Publicado: (2006)

Pharmacy Benefit Spending Poised to Increase for Antithrombotic Drug Therapy--Prasugrel Versus Clopidogrel
por: Curtiss, Frederic R.
Publicado: (2009)

Perspectives on the Generic Cliff--Pushing and Falling
por: Curtiss, Frederic R.
Publicado: (2008)

Irritable Bowel Syndrome and Antidepressants
por: Curtiss, Frederic R.
Publicado: (2008)

Omalizumab and Other New Drug Therapies Occupy a Small Space in Asthma Disease Management
por: Curtiss, Frederic R.
Publicado: (2009)

HEDIS, Beta-Blockers, and What More Can Be Done to Improve Secondary Prevention in ACS
por: Curtiss, Frederic R.
Publicado: (2008)

Relative Value of the NSAIDs, Including COX-2 Inhibitors and Meloxicam
por: Curtiss, Frederic R.
Publicado: (2006)

Atopic March to a Dead End or Does the Theory Really Have Legs?
por: Curtiss, Frederic R.
Publicado: (2007)

In Search of Safe and Effective Oral Anticoagulation
por: Curtiss, Frederic R.
Publicado: (2005)

Looking for the Outcomes We Love in All the Wrong Places: The Questionable Value of Biomarkers and Investments in Chronic Care Disease Management Interventions
por: Curtiss, Frederic R.
Publicado: (2008)

Contradictory Actions on Off-Label Use of Prescription Drugs? The FDA and CMS Versus the U.S. Justice Department
por: Curtiss, Frederic R.
Publicado: (2009)

Rhythm Versus Safety in Amiodarone Therapy
por: Curtiss, Frederic R.
Publicado: (2006)

False-Positive Versus True-Positive Drug-Drug Interactions With Warfarin
por: Curtiss, Frederic R.
Publicado: (2006)

Asthma Disease Management-Evidence-Based Medicine Must Be Dynamic
por: Curtiss, Frederic R.
Publicado: (2006)

More Evolution of the Evidence in Asthma Disease Management-SMART Versus GOAL Clinical Trials Debate the Cost-Benefit of LABA While the Value of Leukotriene Modifiers, Particularly Montelukast, Is Uncertain
por: Curtiss, Frederic R.
Publicado: (2006)

Selectivity and Specificity Are the Keys to Cost-Effective Use of Omalizumab for Allergic Asthma
por: Curtiss, Frederic R.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_ed95nufrtgakrhslkcov9plqe7